GSK de­tails Blenrep’s PhI­II com­bo win as it hopes to stage a turn­around in mul­ti­ple myelo­ma

GSK’s Blenrep in com­bi­na­tion with two oth­er med­i­cines cut the risk of dis­ease pro­gres­sion or death by 59% com­pared to a stan­dard com­bi­na­tion for mul­ti­ple myelo­ma, the phar­ma com­pa­ny an­nounced Mon­day evening.

The study is part of GSK’s bid to bring the can­cer med­i­cine back to mar­ket af­ter yank­ing it from the US in 2022 when a con­fir­ma­to­ry tri­al failed. It had been grant­ed an ac­cel­er­at­ed ap­proval in 2020, though it was on­ly la­beled for a nar­row group of pa­tients and didn’t gen­er­ate ma­jor sales at the time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER